| | Study | Design | Location | Participants | Total, N | Excluded | Period of enrollment | Follow-up duration (median) | Covariates in an adjusted model | NOS score |
| | Conen 2016 [9] | Prospective cohort study | USA | Female health professionals (>45) | 34691 | Prior AF/CA/CVD | 1993–2013 | 19.1 (17.6–19.7) | Age, BMI, HTN, DM, smoke, race, and comorbidity | 9 |
| | Wassertheil 2017 [10] | Prospective cohort study | USA | Postmenopausal women (50–79) | 86046 | NA | From 1994 | 15.9 | Age, race, parity, age at first birth, and cancer-specific potential confounders | 8 |
| | Hung 2018 [11] | Retrospective cohort study | Taipei, China | Individual from 2005 | 5130 | ＜20Y Prior AF/CA | 2005–2010 | 3.4 ± 2 | NA | 8 |
| | Saliba 2018 [12] | Prospective case-control studies | USA and Israel | NA | 19991 | NA | From 1998 | ＞3Y | Age, sex, smoking, alcohol consumption, education, medication use, and comorbidity | 8 |
| | Vinter 2018 [13] | Prospective cohort study | Denmark | NA | 55101 | Nonmelanoma skin cancer | 1993–2013 | 19.7 | Age, BMI, smoking duration, and alcohol consumption, | 7 |
| | Hung 2019 [14] | Prospective cohort study | Taipei, China | NA | 332555 | ＜20Y Prior CA | 1996–2011 | 3.1 (0.97–6.53) | Age, sex, risk factors, and comorbidity | 8 |
|
|
AF, atrial fibrillation; CA, cancer; CVD, cardiovascular disease; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; NA, not applicable; NOS, Newcastle–Ottawa Quality Assessment Scale.
|
